Emad Kandil, Mohammad H Hussein, Kavin Sugumar, Milee Patel, Marika Russell, Gregory Randolph, Eman A Toraih
{"title":"Cytological Alterations of Benign Thyroid Nodules Following Radiofrequency Ablation.","authors":"Emad Kandil, Mohammad H Hussein, Kavin Sugumar, Milee Patel, Marika Russell, Gregory Randolph, Eman A Toraih","doi":"10.1002/lary.32130","DOIUrl":null,"url":null,"abstract":"<p><strong>Background: </strong>Radiofrequency ablation (RFA) has emerged as a minimally invasive treatment for benign thyroid nodules. However, concerns exist about potential cytological progression following RFA. This study investigated the incidence of progression from benign (Bethesda II) to indeterminate (Bethesda III-IV) cytology and evaluated RFA's long-term efficacy and safety.</p><p><strong>Methods: </strong>This prospective study included patients with benign thyroid nodules treated with RFA from July 2019 to December 2023. Pre- and post-ablation fine-needle aspiration (FNA) cytology results were analyzed. Treatment efficacy was assessed through nodular volume changes and thyroid function, while safety was evaluated through complication rates.</p><p><strong>Results: </strong>Among 312 benign thyroid nodules treated with RFA, post-ablation FNA showed 12 cases (3.84%) progressed to Bethesda III, all confirmed benign by Afirma Gene Sequencing Classifier. Three patients underwent surgical resection due to inadequate volume reduction, with histopathology confirming benign nature. RFA achieved sustained nodular volume reduction, with a median reduction rate of 88% at 60 months. The overall complication rate was 3.2%, with no major complications requiring hospitalization.</p><p><strong>Conclusions: </strong>RFA demonstrates low risk of cytological progression and high efficacy in treating benign thyroid nodules. The significant volume reduction and favorable safety profile support RFA as a viable surgical alternative in selected patients. Future studies with larger cohorts and longer follow-up are needed to validate these findings and identify treatment success predictors.</p><p><strong>Level of evidence: 3: </strong></p>","PeriodicalId":49921,"journal":{"name":"Laryngoscope","volume":" ","pages":""},"PeriodicalIF":2.2000,"publicationDate":"2025-03-21","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Laryngoscope","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1002/lary.32130","RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q3","JCRName":"MEDICINE, RESEARCH & EXPERIMENTAL","Score":null,"Total":0}
引用次数: 0
Abstract
Background: Radiofrequency ablation (RFA) has emerged as a minimally invasive treatment for benign thyroid nodules. However, concerns exist about potential cytological progression following RFA. This study investigated the incidence of progression from benign (Bethesda II) to indeterminate (Bethesda III-IV) cytology and evaluated RFA's long-term efficacy and safety.
Methods: This prospective study included patients with benign thyroid nodules treated with RFA from July 2019 to December 2023. Pre- and post-ablation fine-needle aspiration (FNA) cytology results were analyzed. Treatment efficacy was assessed through nodular volume changes and thyroid function, while safety was evaluated through complication rates.
Results: Among 312 benign thyroid nodules treated with RFA, post-ablation FNA showed 12 cases (3.84%) progressed to Bethesda III, all confirmed benign by Afirma Gene Sequencing Classifier. Three patients underwent surgical resection due to inadequate volume reduction, with histopathology confirming benign nature. RFA achieved sustained nodular volume reduction, with a median reduction rate of 88% at 60 months. The overall complication rate was 3.2%, with no major complications requiring hospitalization.
Conclusions: RFA demonstrates low risk of cytological progression and high efficacy in treating benign thyroid nodules. The significant volume reduction and favorable safety profile support RFA as a viable surgical alternative in selected patients. Future studies with larger cohorts and longer follow-up are needed to validate these findings and identify treatment success predictors.
期刊介绍：
The Laryngoscope has been the leading source of information on advances in the diagnosis and treatment of head and neck disorders since 1890. The Laryngoscope is the first choice among otolaryngologists for publication of their important findings and techniques. Each monthly issue of The Laryngoscope features peer-reviewed medical, clinical, and research contributions in general otolaryngology, allergy/rhinology, otology/neurotology, laryngology/bronchoesophagology, head and neck surgery, sleep medicine, pediatric otolaryngology, facial plastics and reconstructive surgery, oncology, and communicative disorders. Contributions include papers and posters presented at the Annual and Section Meetings of the Triological Society, as well as independent papers, "How I Do It", "Triological Best Practice" articles, and contemporary reviews. Theses authored by the Triological Society’s new Fellows as well as papers presented at meetings of the American Laryngological Association are published in The Laryngoscope.
• Broncho-esophagology
• Communicative disorders
• Head and neck surgery
• Plastic and reconstructive facial surgery
• Oncology
• Speech and hearing defects
求助内容：
应助结果提醒方式：
京公网安备 11010802042870号
